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DObjective: The previous Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass
Graft Surgery I (PRIMO-CABG I) trial (n ¼ 3099) indicated that C5 complement inhibition with pexelizumab
might reduce myocardial infarction (MI) and postoperative mortality. PRIMO-CABG II was designed to inves-
tigate the safety and efficacy of terminal complement inhibition in reducing perioperative MI and mortality in
patients undergoing CABG surgery who have 2 or more predefined preoperative risk factors.
Methods: PRIMO-CABG II, a randomized, double-blind, placebo-controlled trial, enrolled 4254 patients un-
dergoing CABG with or without valve surgery at 249 hospitals in North America and Western Europe from
June 2004 to July 2005. The patients were randomly assigned to receive intravenous pexelizumab or placebo.
The primary composite endpoint was the incidence of death or MI within 30 days of randomization.
Results: The PRIMO-CABG II trial did not meet its prespecified primary endpoint of death or MI at 30 days, the
secondary endpoints of death at 30 days, or the development of new or worsening congestive heart failure (rel-
ative risk 0.91, 0.82, and 1.01, respectively; P>.05). However, in a combined analysis of both pivotal trials,
PRIMO-CABG I and II (n ¼ 7353), death at 30 days was significantly reduced for the greatest risk subset
(n ¼ 2156, pexelizumab 5.7% vs placebo 8.1%, P ¼ .024). Furthermore, this mortality reduction persisted
throughout the 180-day follow-up period (pexelizumab 11.1% vs placebo 14.4%, P ¼ .036).
Conclusions: Pexelizumab was associated with a nonsignificant 6.7% reduction in the primary composite end-
point of death or MI at postoperative day 30 in CABG patients enrolled in the PRIMO-CABG II trial, despite the
suggestion of a more favorable treatment effect in the previous PRIMO-CABG I trial. However, an exploratory
analysis of the combined PRIMO I and II data set using an established predictive risk model showed a mortality
benefit for high-risk surgical patients. (J Thorac Cardiovasc Surg 2011;142:89-98)Earn CME credits at
http://cme.ctsnetjournals.org
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Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CHF ¼ congestive heart failure
CPB ¼ cardiopulmonary bypass
MI ¼ myocardial infarction
PRIMO ¼ Pexelizumab for Reduction of
Infarction and Mortality
RR ¼ relative risk
STS ¼ Society of Thoracic Surgeons
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DA previous study (Pexelizumab for Reduction of Infarc-
tion and Mortality in Coronary Artery Bypass Graft Sur-
gery [PRIMO-CABG] I) reported that pexelizumab
treatment was associated with a statistically significant re-
duction in myocardial infarction (MI) or death (11.5% vs
14% for placebo, P ¼ .030) 30 days after surgery in
3099 patients who had undergone CABG surgery with or
without valve surgery.6 The difference between groups
did not reach statistical significance for the primary com-
posite endpoint of death or MI through 30 days for subpop-
ulation of patients undergoing CABG surgery without
valve replacement (n ¼ 2746).6 Enrollment in the
PRIMO-CABG I trial required the presence of 1 or more
predefined patient risk factors, including female gender, re-
cent or multiple MIs, urgent surgery, previous CABG sur-
gery, a history of diabetes mellitus, and advanced age.7-9
These risk factors have been demonstrated to predict
increased morbidity and mortality after CABG7 and are be-
coming increasingly prevalent.10 A post hoc analysis in the
PRIMO-CABG I trial suggested that pexelizumab was ef-
fective in reducing death or MI, compared with placebo,
in patients with 2 or more of these predefined risk factors.11
In addition, a parallel reduction was found in perioperative
MI in the pexelizumab-treated patients that suggested a bi-
ologic mechanism for the associated mortality reduction.
This association was further suggested by the protective ef-
fects of pexelizumab in surgical patients undergoing a pro-
longed aortic crossclamp time (>90 minutes)12 and in
randomized, placebo-controlled studies demonstrating
a significant mortality reduction in ambulatory patients
with acute MI.13
On the basis of these observations, the present PRIMO-
CABG II trial was designed to confirm the efficacy and
safety of pexelizumab in higher risk patients undergoing
CABG surgery requiring CPB. The enrollment criteria
were changed to require the presence of 2 or more prede-
fined risk factors. The pexelizumab dosing, exclusion cri-
teria, and outcome definitions were otherwise identical to
those used in the PRIMO-CABG I trial, with the inten-
tion of enabling analysis of the treatment effect in both
trials.90 The Journal of Thoracic and Cardiovascular SurgeMATERIALS AND METHODS
Patients
The PRIMO-CABG II trial was conducted at 249 sites in 7 North Amer-
ican andWestern European countries. Patients were eligible for enrollment
if they were scheduled for CABG requiring CPB with or without concur-
rent valve surgery and had 2 or more of the following preoperative baseline
risk factors: urgent intervention defined according to the American College
of Cardiology/American Heart Association guidelines9 as requiring hospi-
talization because of medical factors but able to proceed with surgery
within a normal scheduling routine; diabetes mellitus; female gender;
previous CABG; a history of a neurologic event (cerebrovascular accident,
transient ischemic attack, or carotid endarterectomy); a history of conges-
tive heart failure (CHF) (New York Heart Association class III or IV); or
a history of 2 or more MIs (excluding patients who had had an MI within
48 hours before CABG) or of a recent MI that occurred at least 48 hours,
but no more than 4 weeks, before CABG surgery. The exclusion criteria in-
cluded salvage intervention as defined by the American College of Cardi-
ology/American Heart Association guidelines (on-going cardiopulmonary
resuscitation enroute to the operating room)9; current cardiogenic shock,
acute left ventricular rupture, acute ventricular septal rupture, or acute pap-
illary muscle rupture; active infection that the investigator considered clin-
ically significant; known or suspected hereditary complement deficiency;
current or previous participation in any other investigational drug study
or exposure to any investigational drug or device within the previous 30
days; and pregnancy or lactation. The institutional review boards, or equiv-
alent, at each site approved the protocol, and all patients provided written
informed consent. Of those eligible for enrollment, 53%were randomized.
Study Treatment
The patients were randomized in a double-blind fashion using a central
telephone-based system to receive either an intravenous pexelizumab bolus
(2.0 mg/kg) followed by a 24-hour infusion (0.05 mg/kg/h), or placebo
bolus and infusion.5 The bolus was administered as soon as possible after
general anesthesia induction, but not later than 10minutes before CPB. The
dosing regimen was the same as that used in the PRIMO-CABG I trial, in
which profound complement inhibition was demonstrated.6 Stratification
occurred within each site according to the type of surgery planned and
the reoperative status of the patient. The operative techniques and perioper-
ative management were as clinically indicated at each site, with enrollment
predicated on the intended use of CPB with mild to moderate hypothermia.
Definition of Events
Death, defined as all-cause mortality, was assessed through postopera-
tive day 180. MI was defined as a peak creatine kinase-MB of at least
100 ng/mL by postoperative day 4, independent of Q-wave evidence; a cre-
atine kinase-MB of at least 70 ng/mL by postoperative day 4 with Q-wave
evidence of an MI; new Q-wave evidence of MI by postoperative day 30
that was not present by day 4; MI (with or without Q-wave evidence) iden-
tified by the investigator and confirmed by a Clinical Events Committee by
day 30. All MIs were adjudicated by this committee, which remained
unaware of the study treatment. Serum samples were collected at 4, 8,
12, 16, 24, 36, 48, 72, and 96 hours postoperatively for subsequent CK-
MB analysis at a central core laboratory. Electrocardiogramswere recorded
on patient enrollment and at 2, 4, and 30 days postoperatively and were in-
terpreted at a central laboratory whose personnel were unaware of the treat-
ment assignment.Study Endpoints
The prespecified primary endpoint was defined as the incidence of
a composite of death (all causes) or MI (death/MI) through day 30 in pa-
tients undergoing CABG surgery with or without concomitant valve sur-
gery. The secondary endpoints included the incidence of death through
day 30 and day 90, the incidence of new or worsening CHF during the indexry c July 2011
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of new or worsening CHFwas determined by a Clinical Events Committee,
who were unaware of the treatment arm. The tertiary endpoints included
death at day 180, worsening of the New York Heart Association score
from baseline to day 30, and resource use (eg, length of hospital stay, inter-
val in intensive care) through day 180.
Safety
The patients were monitored for adverse events while hospitalized and
at the postoperative day 30 clinic visit. Adverse events were collected using
a cardiac events checklist (completed at days 30, 90, and 180) and a post-
operative infection checklist (completed at days 30, 90, and 180). The
checklists contained prespecified cardiac- or infection-related adverse
events typically reported by CABG surgery patients and were intended
to simplify and standardize the collection of these events.
Statistical Analysis
A sample size of 2000 patients per treatment group was required to pro-
vide 90% power to detect a treatment difference between an anticipated
16% placebo group event rate for the primary endpoint and an anticipated
12% active treatment group event rate using a 2-sided, c2 test and a¼ .05.
The primary efficacy analysis was performed on the binary composite
endpoint (death or MI through day 30) for all randomized patients (the
intent-to-treat population). A comparison of the incidence rates between
the treatment groups was performed using c2 testing with stratification ac-
cording to the type of surgery (CABG with or without valve surgery, mitral
or other valve surgery, first or repeat CABG). The sensitivity analysis of the
day 30 composite endpoint included an analysis of each component, as well
as an analysis of the day 4 composite endpoint and each of its components.
Survival analysis was performed on the mortality data and included
Kaplan-Meier curve estimation and Cox proportional hazard modeling.
The log-rank test was used to test the difference in the time-to-event be-
tween the 2 treatment groups. The consistency of the treatment effect
was evaluated using subgroup analyses based on a number of characteris-
tics (eg, predetermined risk factors, age, sex, race, preoperative medica-
tions, intraoperative blood-sparing agents, and other surgical conduct
variables). Other endpoints were analyzed using nonparametric rank anal-
ysis (continuous endpoints) and stratified c2 testing (binary endpoints).
A secondary analysis was performed in which the predefined risk fac-
tors were weighted using mapped coefficients derived in the Society of
Thoracic Surgeons (STS) National Database mortality risk algorithm7 to
create a single mortality risk probability for each patient (post hoc). Miss-
ing risk factor coefficients were imputed to the STS national mean (2004
data harvest) for continuous variables, to the lowest risk for categorical var-
iables, and to the gender-specific mean for body surface area. The baseline
characteristics were summarized by treatment group and assessed for dif-
ferences between treatment groups using a t test (continuous variables) or
c2 test (for categorical variables).
Data from the PRIMO-CABG II trial (n¼ 4254) were analyzed individ-
ually and then pooled with data from the PRIMO-CABG I trial (n¼ 3099)
for subsequent analysis. STS predictive algorithms for mortality could be
applied to 95% of the 7353 patients. The STS predictive algorithms
were not assignable to patients with more than 1 valve operation or in pa-
tients who did not undergo CABG. The data collection forms, data defini-
tions, and drug infusion protocols were identical for the 2 pivotal trials.
Statistical Analysis Systems, version 8.2, and S-Plus, version 2000 (SAS
Institute, Cary, NC), were used for all statistical analyses.
RESULTS OF PRIMO-CABG II TRIAL
Patient Characteristics and Disposition
A total of 4254 patients undergoing CABG with or with-
out valve surgery were randomized and complete data col-
lected for all but 37 who were lost to follow-up (Figure 1).The Journal of Thoracic and CThe baseline characteristics were similar in the 2 treatment
groups (Table 1).
Efficacy
Pexelizumab was associated with a nonsignificant 6.7%
reduction in the primary composite endpoint, death or MI,
compared with placebo (15.2% [323/2130] vs 16.3 %
[341/2098], P ¼ .20) (Table 2). The incidence of periopera-
tive MI through day 30 (relative risk [RR] 0.93, P ¼ .31),
death at 30 days (RR 0.82, P ¼ 0.18), and death at 90 days
(RR 0.92, P¼ .51) were also reduced insignificantly. The de-
velopment of new or worsening CHF (RR 1.01, P¼ .93) was
unaffected by pexelizumab. The duration of aortic cross-
clamping did not appear to differentially influence the inci-
dence of the primary endpoint of 30-day death or MI when
pexelizumab was administered rather than placebo.
Association of Efficacy With Predetermined Risk
Factors
Insignificant trends were noted associating pexelizumab
treatment with reduced mortality for each of the predeter-
mined risk factors, except for previous MI. Pexelizumab
efficacy was not increased with an increasing number of
risk factors per patient (Table 3). The prespecified subgroup
analysis, with the patients stratified by type of cardiac sur-
gery, showed similar nonsignificant trends of a pexelizumab
reduction of the primary composite endpoint (Table 4).
Safety
The number and proportion of patients experiencing ad-
verse events was similar in both treatment groups. The inci-
dence of allergic reactions was similar in the 2 treatment
groups (placebo 0.2%; pexelizumab 0.7%). The most fre-
quent adverse events in both groups were atrial fibrillation,
conduction disorders, and clinical CHF. No clinically im-
portant differences were seen between the 2 groups in the
adverse or cardiac adverse event profiles. Also, the infection
logs showed no differences in overall infection at 30, 60,
and 90 days after the procedure (placebo 22.7%, 26.6%,
and 28.0% vs pexelizumab 22.2%, 26.4%, and 27.9%, re-
spectively). No meaningful or consistent differences were
seen between the 2 treatment groups in the incidence or
types of postoperative infection, except for a significant re-
duction in the prevalence of postoperative sepsis (4.5%
through 180 days for placebo vs 3.0% for pexelizumab in
the PRIMO-CABG II trial; RR 0.66, 95% CI 0.48 to
0.91; P ¼ .01. This effect was also significant in the
PRIMO-CABG I and II combined randomized database
(4.0% for placebo vs 2.6% for pexelizumab).
EXPLORATORYANALYSIS AND COMBINED
RESULTS OF PRIMO-CABG I AND II TRIALS
Extensive analysis was performed to understand the in-
ability of the PRIMO-CABG II trial to replicate the findingsardiovascular Surgery c Volume 142, Number 1 91
FIGURE 1. Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery (PRIMO-CABG) II patient flow diagram.
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provide a comprehensive analysis of all randomized CABG
patients to place any potential role for pexelizumab in per-
spective. A review of the samples of the study drug indicated
that the expected potency of the treatment agent was present.
Comparison of PRIMO-CABG II to PRIMO-CABG
I Trials
Substantial baseline differences were seen in the patients
enrolled in the 2 trials. By design, the incidence of prede-
fined risk factors and the number of risk factors per patient
was greater in the PRIMO-CABG II than in the PRIMO-
CABG I patients (Table 5). The most striking and unantic-
ipated difference was that PRIMO-CABG II patients
compared with PRIMO-CABG I patients were treated
more frequently with preoperative statins (76.4% vs
22.9%) and with intraoperative aprotinin (50.0% vs
25.1%). The use of aprotinin was associated with an in-
creased prevalence of surgical risk and the number of risk
factors; however, the relative mortality reduction afforded92 The Journal of Thoracic and Cardiovascular Surgeby pexelizumab was unaffected by either aprotinin or statin
use (data not shown).
Prespecified Outcome Analysis of Merged PRIMO-
CABG II and I Database
Analysis of the PRIMO-CABG II trial data merged with
the PRIMO-CABG I trial data (n ¼ 7353) showed that the
composite endpoint of death or MI at 30 days was signifi-
cantly reduced, occurring in 501/3679 pexelizumab-treated
patients compared with 556/3637 placebo-treated patients
(RR 0.88, 95% CI 0.79 to 0.98; P ¼ .0198). The secondary
endpoint of all-cause death was insignificantly reduced,
however, with a RR of 0.79 at 30 days (P ¼ .054), 0.87 at
90 days (P ¼ .134), and 0.86 at 180 days (P ¼ .074).
Analysis of Predefined Risk Factors and Their
Relationship to Predicted Surgical Risk
The enrollment design of the PRIMO-CABG II trial was
based on the favorable effect of pexelizumab seen in the
high-risk subset of the PRIMO-CABG I patients who hadry c July 2011
TABLE 1. PRIMO-CABG II: baseline demographic and anthropometric characteristics (all randomized patients)
Characteristics Placebo (n ¼ 2112) Pexelizumab (n ¼ 2142) P value
Age (y)* 66.2 (35–90) 66.2 (31–91) .80
Left ventricular ejection fraction* 50.4 (49.7–51.0) 50.5 (49.8–51.1) .85
Predicted mortality* 0.028 (0.026–0.029) 0.028 (0.026–0.030) .63
Diabetes mellitus 1246 (59.0) 1298 (60.6) .29
Urgent surgery 1534 (72.6) 1517 (70.8) .19
Previous CABG 199 (9.4) 228 (10.6) .18
History of heart failure 843 (40.0) 838 (39.1) .60
History of neurologic event 485 (23.0) 506 (23.6) .61
Female sex 852 (40.3) 839 (39.2) .29
Preoperative statin 1609 (76.2) 1639 (76.5) .97
Aprotinin 1020 (48.3) 1085 (50.7) .12
Investigator country .99
Canada 73 (3.5) 70 (3.3)
Germany 374 (17.7) 374 (17.5)
France 125 (5.9) 127 (5.9)
United Kingdom 34 (1.6) 31 (1.4)
The Netherlands 84 (4.0) 92 (4.3)
United States of America 1422 (67.3) 1448 (67.6)
Data are presented as n (%), unless otherwise specified. *Data are presented as mean (95% confidence interval). P values for age are from t test, P value for sex from Fisher’s exact
test; and P value for investigator country from c2 test. PRIMO-CABG, Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery; CABG,
coronary artery bypass graft.
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of the number of risk factors, rather than the number and
predictive value of each risk factor, as an inclusion criterion,
resulted in enrollment in the PRIMO-CABG II trial of a sig-
nificant number of patients who actually had a low pre-
dicted risk.
To better characterize the relationship between the preop-
erative risk and the pexelizumab effect, the predicted oper-
ative mortality was calculated for each patient using the
STS mortality risk coefficients for CABG and CABG/valveTABLE 2. PRIMO-CABG II: effect of pexelizumab treatment on all-caus
Endpoints
Placebo (n ¼ 2112)
n Denominator (%) n
Days 0–4
Composite 279 2103 (13.3) 28
Death 36 2103 (1.7) 4
MI 258 2112 (12.2) 25
Non–Q-wave infarction 219 2112 (10.4) 19
Q-wave infarction 39 2112 (1.9) 5
Days 0–30
Composite 341 2098 (16.3) 32
Death 96 2098 (4.6) 8
MI 280 2112 (13.3) 26
Non–Q-wave infarction 225 2112 (10.7) 20
Q-wave infarction 55 2112 (2.6) 6
Days 0–90
Death 135 2083 (6.5) 12
Days 0–180
Death 168 1611 (10.4) 15
RR and 95% CI ¼ stratified by (CABG/previous CABG and valve surgery) pexelizumab t
vious CABG and valve surgery. PRIMO-CABG, Pexelizumab for Reduction of Infarction an
graft; RR, relative risk; CI, confidence interval; MI, myocardial infarction.
The Journal of Thoracic and Csurgery toweigh their relative contribution to mortality risk.
Overall, the mean PRIMO-CABG II trial predicted opera-
tive mortality rate was 2.8%, significantly greater than the
2.1% rate calculated for the PRIMO-CABG I trial.
The mean predicted risk of PRIMO-CABG I patients was
2% for the subset with 2 predefined risk factors (the mini-
mum entry criterion for PRIMO-CABG II). On average,
PRIMO-CABG II patients includedmore patients with mul-
tiple risk factors and more patients with a predicted risk
greater than 2% than were enrolled in the PRIMO-CABGe mortality and myocardial infarction
Pexelizumab (n ¼ 2142)
RR (95% CI) P valueDenominator (%)
0 2135 (13.1) 0.96 (0.83–1.12) .65
0 2135 (1.9) 1.10 (0.69–1.75) .77
1 2142 (11.7) 0.93 (0.80–1.09) .39
6 2142 (9.2) 0.86 (0.72–1.02) .09
5 2142 (2.6) 1.25 (0.83–1.90) .14
3 2130 (15.2) 0.91 (0.80–1.05) .20
1 2130 (3.8) 0.82 (0.61–1.10) .18
9 2142 (12.6) 0.93 (0.79–1.08) .31
0 2142 (9.3) 0.85 (0.71–1.02) .08
9 2142 (3.2) 1.15 (0.81–1.64) .27
9 2123 (6.1) 0.92 (0.73–1.17) .51
1 1635 (9.2) 0.87 (0.71–1.07) .20
o placebo ratio. P value from Cochran-Mantel-Haenszel test stratified by CABG/pre-
d Mortality in Coronary Artery Bypass Graft Surgery; CABG, coronary artery bypass
ardiovascular Surgery c Volume 142, Number 1 93
TABLE 3. PRIMO-CABG II: primary composite endpoint (all-cause mortality or myocardial infarction) through day 30 stratified by baseline risk
factors
Baseline group
Placebo Pexelizumab
P valuen (%) N n (%) N RR (95% CI)
Female sex 150 (17.7) 846 134 (16.2) 827 0.91 (0.74–1.13) .38
Diabetes 182 (14.7) 1238 184 (14.2) 1293 0.93 (0.77–1.12) .49
CHF 172 (20.5) 839 159 (19.0) 835 0.89 (0.73–1.07) .34
MI 103 (14.7) 700 99 (15.1) 657 1.03 (0.81–1.32) .85
Neurologic event 93 (19.3) 482 89 (17.7) 504 0.91 (0.71–1.17) .44
Urgent intervention 232 (15.3) 1521 208 (13.8) 1507 0.89 (0.75–1.05) .16
Previous CABG 66 (33.2) 199 76 (33.5) 227 0.98 (0.74–1.29) .94
>2 Risk factors 338 (16.3) 2077 320 (15.2) 2112 0.91 (0.79–1.04) .18
>3 Risk factors 213 (19.1) 1116 196 (17.6) 1115 0.90 (0.76–1.07) .26
>4 Risk factors 86 (20.3) 424 84 (21.2) 397 0.95 (0.73–1.24) .96
P value is from Cochran-Mantel-Haenszel test stratified by CABG/previous CABG and valve surgery. N, Number of patients randomized in treatment group at risk of composite
endpoint; CHF, congestive heart failure; other abbreviations as in Table 2.
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DI trial (Figure 2). However, a histogram of the predicted risk
frequency for the 2 trials showed the relative similarity of
the risk profiles in the PRIMO-CABG I and PRIMO-
CABG II trials despite the increased prevalence of multiple
risk factors in the latter trial (Figure 3). Only 33% of
PRIMO-CABG II patients were subsequently determined
to have a predicted risk of 2% or greater, despite the inten-
tion to evaluate pexelizumab in a higher risk patient popu-
lation than that evaluated in the PRIMO-CABG I trial.
Accordingly, the pooled data of the PRIMO-CABG I and
II trials were analyzed by dividing the data set into 2 groups,
the 2% or greater predicted mortality rate of the 2-risk fac-
tor PRIMO-CABG I trial patients or less than 2% (Table 6).
The high-risk CABG-only subgroup (22% of the enrolled
CABG patients) had a significant 21.8% reduction
(P<.05) in the prespecified composite endpoint (death or
MI through 30 days). A nonsignificant trend in mortality re-
duction was observed at day 30 (25.5%), day 90 (19.8%)
and through day 180 (17.3%). The entire high-risk sub-
group, including those undergoing concomitant valve pro-
cedures (31% of all enrolled patients), experienced
a significant and persistent mortality benefit from pexelizu-
mab treatment compared with placebo. The risk reduction
for death or MI through day 30 (P ¼ NS), death at 30
days, death at 90 days (P ¼ NS), and death at 180 days
was 12%, 30.3%, 21.5%, and 21.4%, respectively. The pa-TABLE 4. PRIMO-CABG II: primary composite endpoint (all-cause mort
Baseline group
Placebo
n (%) N
Primary CABG 275 (14.5) 1899 24
Previous CABG 66 (33.2) 199 7
CABG plus valve surgery 94 (28.8) 326 9
CABG only 247 (13.9) 1772 22
Nonmitral valve surgery 58 (27.2) 213 5
Mitral valve surgery 36 (31.9) 113 4
P value is from Cochran-Mantel-Haenszel test stratified by CABG/previous CABG and val
endpoint; other abbreviations as in Table 2.
94 The Journal of Thoracic and Cardiovascular Surgetients with a predicted mortality risk of less than 2% had no
discernable benefit or additional risk trend with pexelizu-
mab compared with placebo.
The Kaplan-Meier survival curves for all PRIMO-CABG
I and PRIMO-CABG II patients and for the high- and low-
predicted mortality groups are illustrated in Figure 4. A sig-
nificant survival advantage (P ¼ .042) is shown for
pexelizumab-treated patients having an STS predicted mor-
tality of 2% or greater. However, pexelizumab appeared to
confer no survival hazard or advantage compared with pla-
cebo for low-risk patients, those with an STS predicted mor-
tality rate of less than 2%.
The STS National Adult Cardiac Database reported on
281,347 CABG or CABG/valve procedures from January
2005 to June 2006, with the finding that 35.9% of the
CABG patients and 45% of all the patients would have
met the 2% predicted mortality threshold for pexelizumab
effectiveness.14 Thus, despite the intention to enroll high-
risk patients, both pivotal trials enrolled patients with
a lower risk profile than typically seen in clinical practice.
DISCUSSION
Effectiveness of Pexelizumab for All Enrolled
Patients
Although the data from the PRIMO-CABG II trial recon-
firmed the previously established safety of administeringality or myocardial infarction) through day 30 by randomized stratum
Pexelizumab
RR (95% CI) P valuen (%) N
7 (12.98) 1903 0.89 (0.76–1.04) .17
6 (33.48) 227 0.98 (0.74–1.29) .94
5 (27.86) 341 0.92 (0.72–1.18) .54
8 (12.74) 1789 0.91 (0.77–1.07) .26
1 (24.88) 205 0.90 (0.66–1.23) .43
4 (32.35) 136 0.96 (0.66–1.41) .98
ve surgery. N, Number of patients randomized in treatment group at risk of composite
ry c July 2011
TABLE 5. Comparative preoperative patient characteristics
Variable
PRIMO-CABG I
(n ¼ 3099) (%)
PRIMO-CABG II
(n ¼ 4254) (%)
Previous CABG 8.4 10.0
History of CHF 30.5 39.5
CABG plus valve procedure 11.8 16.3
Previous neurologic event 14.3 23.3
Female sex 26.8 39.5
History of MI 11.3 54.8
Diabetes 41.0 59.8
 2 Previous MIs 20.3 32.0
Urgent surgery 63.7 71.7
1 Risk factor 37.6 7.5
2 Risk factors 36.2 47.9
3 Risk factors 18.7 30.7
4 Risk factors 5.0 12.0
5 Risk factors 0.9 1.8
6 Risk factors 0.0 0.1
Preoperative statin use 22.9 76.4
Aprotinin use 25.1 50.0
CHF, Congestive heart failure; other abbreviations as in Table 2.
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C
Da C5 terminal complement inhibitor,6 its efficacy could not
be conclusively demonstrated. The previously reported re-
lationship between the predefined patient risk factors and
treatment effect was not demonstrable in the PRIMO-
CABG II trial. The PRIMO-CABG II trial was designed
to enroll patients with greater prospective risk and, there-
fore, to enrich the population studied with patients who
showed a positive treatment effect for MI reduction and0
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FIGURE 2. Enrollment characterized by number of risk factors and Society of T
Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery
factors shown in light bars for PRIMO-CABG I and dark bars for PRIMO-CAB
risk factor group shown as light line and point estimate for PRIMO-CABG I an
predicted mortality risk is calculated risk equivalent for 2 or more risk factors
The Journal of Thoracic and Can associated mortality reduction in the previously executed
PRIMO-CABG I trial. However, because the trial was not
powered to demonstrate an independent mortality reduc-
tion, the absence of a robust treatment effect on MI resulted
in failure to significantly affect the composite endpoint.
When all the randomized patients from the PRIMO-
CABG I and II trials (n ¼ 7353) were considered, a statisti-
cally significant reductionwas seen in the primary composite
endpoint of death or MI at 30 days; however, the efficacy
trend for mortality alone remained insignificant through
postoperative day 180 (risk reduction 14%, P ¼ .074). The
mechanismofmortality reduction in cardiac surgery patients
was not clarified by the results from the PRIMO-CABG II
trial. The absence of a significant favorable treatment effect
of pexelizumab on reducing myocardial damagewas consis-
tent with the results of the Assessment of Pexelizumab in
Acute Myocardial Infarction (APEX) trial,15 which showed
no benefit of pexelizumab in patients with acute MI treated
with percutaneous intervention. Furthermore, the reported
relationship between prolonged induced cardiac ischemia
and treatment effect12 was also not demonstrable.Study Limitations
The most striking differences between the PRIMO-
CABG II study population and the previously studied
patients in the PRIMO-CABG I trial were the increased
enrollment of very high-risk patients and the increased use
of aprotinin and statins. Both aprotinin and statins have pow-
erful anti-inflammatory effects,16-18 which might have3 Risk Factors 4+ Risk Factors
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G II. Society of Thoracic Surgeons (STS) predicted mortality risk for each
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FIGURE 3. Histogram of number of enrolled patients in Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery
(PRIMO-CABG) I (gray line) compared with PRIMO-CABG II (black line). Calculated average intended enrollment threshold for PRIMO-CABG II (ver-
tical line) placed at 2% predicted mortality.
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D reduced the adverse effect of the systemic inflammatory
response generated during CPB and cardiac surgery.19
The increased use of these agents might, therefore, have
blunted the efficacy of pexelizumab. Aprotinin, in particular,TABLE 6. PRIMO-CABG I and II risk reduction by predicted mortality
CABG only
STS predicted mortal
<2%
Patients (n) 4687
% 78%
Death or MI through day 30
Pexelizumab 9.66%
Placebo 10.41%
Risk reduction 7.2%
P value .41
Death through 30 days
Pexelizumab 2.03%
Placebo 1.95%
Risk reduction 4.1%
P value .92
Death through 90 days
Pexelizumab 2.71%
Placebo 2.61%
Risk reduction 3.8%
P value .86
Death through 180 days
Pexelizumab 3.28%
Placebo 3.32%
Risk reduction 1.2%
P value 1
STS, Society of Thoracic Surgeons; other abbreviations as in Table 2.
96 The Journal of Thoracic and Cardiovascular Surgewas administered more frequently in the higher risk subset of
the PRIMO-CABG II patients, for whom the pexelizumab ef-
fect was expected to be greater. Compared with the PRIMO-
CABG I trial, in which the relationship between risk andin patients receiving CABG and all patients
All patients
ity STS predicted mortality
 2% <2%  2%
1340 4804 2156
22% 69% 31%
14.88% 9.6% 19.9%
19.04% 10.3% 22.6%
21.8% 6.9% 12.0%
.049 .41 .12
5.52% 2.0% 5.7%
7.41% 1.9% 8.1%
25.5% 3.1% 30.3%
.18 .87 .024
8.78% 2.7% 9.0%
10.95% 2.6% 11.5%
19.8% 6.7% 21.5%
.20 .72 .06
11.02% 3.3% 11.1%
13.32% 3.3% 14.1%
17.3% 0.6% 21.4%
.21 .96 .036
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FIGURE 4. Kaplan-Meier survival curves illustrated for combined patients enrolled in Pexelizumab for Reduction of Infarction andMortality in Coronary
Artery Bypass Graft Surgery (PRIMO-CABG) I and II stratified by predicted mortality risk. (A) Survival in patients with predicted mortality<2% with
pexelizumab treatment (dark line) compared with placebo (gray line). (B) Survival in patients with predicted mortality of 2% or greater with pexelizumab
treatment (dark line) compared with placebo (gray line).
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A
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Dpexelizumab effect was demonstrated, aprotinin was used al-
most twice as frequently andmight have reduced the ability to
identify the true treatment effect of pexelizumab. The mech-
anism of this interaction has yet to be identified.
As with all clinical trials, the ability to generalize these
results was limited by the selective trial enrollment and
a changing treatment environment. This was particularly
true for this trial, in which aprotinin is no longer available
and virtually all patients are now treated with statins before
and after surgical intervention.The Journal of Thoracic and CEffectiveness of Pexelizumab for High-Risk CABG
and CABG/Valve Patients
Pexelizumab appears to be safe and effective in reducing
mortality for high-risk CABG and CABG/valve patients.
When the patients were stratified according to a validated pre-
dicted mortality risk using the STS National database algo-
rithm, those with a predicted risk of 2% or more experienced
a significant reduction in mortality that persisted through 180
days. The STS National Cardiac Database has indicated that
in contemporaneous U.S. practice, 45% of patients meet thisardiovascular Surgery c Volume 142, Number 1 97
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A
C
Dthreshold criterion. Thus, the mortality reduction afforded
through pexelizumab use could be substantial.
CONCLUSIONS
The previously identified efficacy of pexelizumab in re-
ducing perioperative MI and its increased effectiveness dur-
ing prolonged surgically induced ischemia were not
apparent in the PRIMO-CABG II trial. Although not meet-
ing its primary endpoint, which was a composite variable of
death or MI, the results of the present trial were consistent
with previous investigations that suggested that pexelizu-
mab reduces mortality in patients undergoing CABG sur-
gery through its complement inhibiting properties in
properly selected patients. This favorable treatment effect
was significant in the highest risk patients, including those
with preoperative characteristics associated with a predicted
mortality rate of 2% or more. These patients account for an
estimated 45% of all CABG and CABG/valve surgery per-
formed in the United States.
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